Britain and America have secured a important bilateral deal that will preserve zero duties on UK drug shipments going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to boost spending on medicines through the public health system. This pledge guarantees that duties on these key exports will remain at nothing for a timeframe of the next three years.
This agreement is in response to previous statements to dramatically increase tariffs on branded pharmaceutical imports, with increases discussed as high as one hundred percent.
"This agreement with the United Kingdom bolsters the global environment for cutting-edge drugs and brings long-overdue balance to U.S.–U.K. pharmaceutical trade," an announcement said.
Commercial Impact
Drugs represent one of the UK's most significant export categories to the United States, which is clearly the largest destination for major companies like GSK and AstraZeneca.
Export figures show that in the year to the end of last September, the UK sold pharmaceutical products valued at £11.1bn to the US. This value represented nearly one-fifth of British export trade in that timeframe.
"This deal secures work, stimulates investment and sets the stage for the UK to emerge as a international leader for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The pact involves several key commitments from the United Kingdom:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must return to the NHS to stay within budget will be capped at 15%. In the past, refunds were more than twenty percent.
Recent Tensions
The pact comes amid a ongoing tension between the drug companies and the UK government over medicine costs and approval rates.
This friction were exacerbated by claims that US patients were charged a premium for the equivalent treatments than people in the UK and Europe.
In recent months, several large pharmaceutical investments in the UK have been halted or abandoned, while major funding commitments have been directed toward American operations.
One official stated that the NHS had to increase expenditure on treatments, noting that its spending on drugs had shrunk as a proportion of its overall budget over the last ten years.
